Cargando…
Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges
The coronavirus disease (COVID-19) pandemic is sweeping the globe. Even with a number of effective vaccines being approved and available to the public, new cases and escalating mortality are climbing every day. ACE2 (angiotensin-converting enzyme 2) is the primary receptor for the COVID-19 causative...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Thoracic Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008810/ https://www.ncbi.nlm.nih.gov/pubmed/33296619 http://dx.doi.org/10.1165/rcmb.2020-0322PS |